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AbstrACt
background Natural killer and cytotoxic CD8+ T cells 
are major players during antitumor immunity. They 
express NKG2D, an activating receptor that promotes 
tumor elimination through recognition of the MHC class 
I chain- related proteins A and B (MICA and MICB). Both 
molecules are overexpressed on a great variety of tumors 
from different tissues, making them attractive targets 
for immunotherapy. However, tumors shed MICA and 
MICB, and the soluble forms of both (sMICA and sMICB) 
mediate tumor- immune escape. Some reports indicate 
that anti- MICA antibodies (Ab) can promote the restoration 
of antitumor immunity through the induction of direct 
antitumor effects (antibody- dependent cell- mediated 
cytotoxicity, ADCC) and scavenging of sMICA. Therefore, 
we reasoned that an active induction of anti- MICA Ab 
with an immunogenic protein might represent a novel 
therapeutic and prophylactic alternative to restore 
antitumor immunity.
Methods We generated a highly immunogenic chimeric 
protein (BLS- MICA) consisting of human MICA fused to the 
lumazine synthase from Brucella spp (BLS) and used it to 
generate anti- MICA polyclonal Ab (pAb) and to investigate 
if these anti- MICA Ab can reinstate antitumor immunity 
in mice using two different mouse tumors engineered 
to express MICA. We also explored the underlying 
mechanisms of this expected therapeutic effect.
results Immunization with BLS- MICA and administration 
of anti- MICA pAb elicited by BLS- MICA significantly 
delayed the growth of MICA- expressing mouse tumors 
but not of control tumors. The therapeutic effect of 
immunization with BLS- MICA included scavenging of 
sMICA and the anti- MICA Ab- mediated ADCC, promoting 
heightened intratumoral M1/proinflammatory macrophage 
and antigen- experienced CD8+ T cell recruitment.
Conclusions Immunization with the chimeric 
protein BLS- MICA constitutes a useful way to actively 
induce therapeutic anti- MICA pAb that resulted in a 
reprogramming of the antitumor immune response 
towards an antitumoral/proinflammatory phenotype. 
Hence, the BLS- MICA chimeric protein constitutes a novel 
antitumor vaccine of potential application in patients with 
MICA- expressing tumors.
bACkground
An improved understanding of the cellular 
and molecular mechanisms that regulate 
tumor growth in immunocompetent hosts 
made possible the design of strategies aimed 
at restoring antitumor immunity, collectively 
known as immunotherapies.1 However, such 
strategies must overcome the ability of tumor 
cells to evade immune cell effector functions, 
a phenomenon that arises during tumor 
growth under immunological pressure.2 
Therefore, potentially successful approaches 
to improve clinical success focus on devel-
oping and combining novel strategies that 
improve tumor- specific immunity and at 
the same time, interfere with tumor escape 
mechanisms.
Natural killer (NK) cells and cytotoxic 
CD8+ T lymphocytes (CTL) are major players 
of antitumor immunity. NK cells recognize 
and eliminate tumor cells through an array 
of activating receptors among which CD16 
(that recognizes the Fc portion of IgG and is 
responsible for the antibody- dependent cell- 
mediated cytotoxicity, ADCC) and NKG2D are 
the most relevant. In humans, NKG2D recog-
nizes MICA and MICB, as well as members 
of the UL-16- binding protein (ULBP)/
retinoic acid early transcripts family.3 Alto-
gether, these NKG2D ligands (NKG2DL) are 
expressed on a wide variety of tumors but 
weakly expressed on healthy cells.3 Although 
overexpression of NKG2DL may represent a 
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tumors display escape strategies that subvert the biolog-
ical function of NKG2D.6 7 The underlying mechanisms 
through which these ‘immunoevasion’ phenotypes resist 
NKG2D- dependent cytotoxicity involve the proteolytic 
shedding of MICA and other NKG2DL induced by tumor- 
secreted metalloproteases.6–8 Released soluble MICA 
(sMICA) can thereafter bind to NKG2D and induce its 
downmodulation and degradation. In addition, other 
mechanisms account for low cell surface expression of 
MICA and impaired recognition by NKG2D, as we have 
demonstrated previously.9
It has been shown that Ab- mediated blockade of CTLA4 
in mouse models induced a strong antitumor immu-
nity10 and clinical studies with antagonistic anti- CTLA4 
Ab demonstrated that it is possible to boost antitumor 
immunity in patients with melanoma.11 Notably, admin-
istration of anti- CTLA4 monoclonal Ab (mAb) induced 
anti- MICA Ab in some patients that cleared sMICA and 
interfered with tumor- immune escape.12 13 Additionally, 
the therapeutic efficacy of mAb- mediated neutraliza-
tion of sMICA14 or MICA shedding15 has been shown to 
negatively affect tumor growth in mouse models. In addi-
tion, it has been demonstrated that immune complexes 
formed between a mAb and the α3 domain of MICA can 
activate human NK cells in a Fc- dependent manner.16 
Monoclonal Ab- mediated therapeutic approaches are 
mostly useful for patients with clinically evident tumors 
and there are some adjuvant treatment options such as 
chemotherapy, radiation therapy, hormone therapy, and/
or immunotherapy administered to patients with cancer 
after surgical excision, chemotherapy or radiotherapy of 
the primary tumor. However, the efficacy of most of these 
adjuvant therapies is not quite high and many patients 
remain at risk of tumor recurrence of the primary 
tumor and/or development of metastases. Therefore, 
we hypothesized that active induction of anti- MICA Ab 
may trigger beneficial effects in tumor- bearing hosts and 
exert a beneficial effect through multiple mechanisms 
such as clearing of sMICA from serum and promoting 
ADCC against tumor cells. Taking advantage of an estab-
lished platform suitable to produce highly immunogenic 
chimeric proteins17 18 that displays intrinsic adjuvant 
properties and can induce specific Ab,19 the objectives of 
this study were to produce a chimeric protein consisting 
of the ectodomain of MICA fused to BLS to generate 
an immunogen useful for the induction of anti- MICA 
Ab in tumor- bearing hosts, to investigate whether these 




Data of expression of different NKG2DL in human 
tumors were obtained from the cBioportal (http://www. 
cbioportal. org/).20 21
Ab and reagents
The following mAbs were used: unlabeled and phyco-
erythrin (PE)- labeled anti- human MICA/B (clone 6D4, 
Biolegend), AlexaFluor488- labeled anti- human MICA 
(clone 159227, Biotechne), allophycocyanin (APC)- 
labeled anti- human MICB (clone 236511, Biotechne), 
PE- labeled anti- F4/80 (clone BM8, Biolegend), PE- la-
beled, fluorescein isothiocyanate (FITC)- labeled 
and PerCP/Cy5.5- labeled anti- CD3ε (clone 17A.2; 
Biolegend), APC- labeled anti- CD8α (clone 53-6.7, 
Biolegend), FITC- labeled anti- CD4 (clone RM4-5; 
Biolegend), APC/Cy7- labeled anti- CD11b (clone M1/70, 
Biolegend), PE/Cy7- labeled anti- CD11c (clone N418, 
Biolegend), PE/Cy7- labeled anti- Gr-1 (clone RB6.8C5, 
Biolegend), PerCP/Cy5.5- labeled anti- CD45R/B220 
(clone RA3- 6B2, Biolegend), FITC- labeled anti- CD86 
(clone GL-1, Biolegend), PE/Cy7- labeled anti- CD44 
(clone IM7, Biolegend), APC- labeled anti- MHC- II (I- A/E, 
clone M5/114, Biolegend), PE/Cy7- labeled anti- CD274 
(PD- L1, clone 10F.9G2, Biolegend) and PerCP/Cy5.5- 
labeled anti- CD206 (clone C068C2, Biolegend). Also, 
a previously obtained anti- MICA/B mAb (D7, IgG2b), 
an anti- BLS mAb (BI24, IgG2b) and rabbit pAb raised 
against peptides spanning the α1 or the α2 domain of 
human MICA were used.22–24 FITC- labeled or PE- labeled 
anti- mouse IgG (Biolegend) and HRP- labeled anti- mouse 
or anti- rabbit IgG (Bio- Rad) were also used.
Production of chimeric bLs-MICA protein
Exons 2 to 4 of human MICA*001 (that encode for the 
full ectodomain), http://www. ebi. ac. uk/ ena/ data/ view/ 
AH008148, were synthesized including an upstream 
sequence for cloning with NsiI (ATGCAT), a downstream 
linker (GGTAGC) followed by a downstream sequence 
for cloning with AflII (CTTAAG), and cloned into the 
pET11a plasmid containing the open reading frame 
of Brucella spp lumazine synthase (BLS) as previously 
reported.17 Of note, as exon 3 contains a NsiI cutting 
sequence (ATGCAT), this sequence was replaced by the 
silent substitution ATGCAC. The plasmid was used to 
transform Escherichia coli BL21 (DE3)- competent cells for 
expression of the recombinant protein (429 aminoacids; 
expected size: 48.6 kDa, assessed with the ProtParam tool; 
http:// web. expasy. org/ protparam/). The sequences of 
the ectodomain of MICA*001, the peptide linker and 
BLS are shown in table 1. Expression of the chimeric 
recombinant protein was induced with isopropyl-β-d-
1- thiogalactopyranoside, and bacteria were lysed with 
50 mM Tris–HCl, 5 mM EDTA, 40 µg/mL deoxyribonu-
clease (DNase), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), pH 8.0 and sonication. Inclusion bodies were 
solubilized in 100 mM Tris, 50 mM glycine, 5 mM EDTA, 
8 M urea, pH 8.0 at room temperature overnight with 
agitation. The solubilized proteins were purified by anion 
exchange chromatography in a Q Sepharose (Phar-
macia, GE Healthcare Life Sciences) column using a high 
performance liquid chromatography (HPLC) equipment 
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BLS, Brucella lumazine synthase; BLS- MICA, BLS coupled to MICA; MICA, MHC class I chain- related protein A.
Elution was performed using a linear gradient between 0 
M and 1 M NaCl in a 50 mM Tris–HCl, 8 M urea, 50 mM 
glycine, pH 8 buffer. The elution fraction containing the 
recombinant protein, determined by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), 
was refolded by sequential dialysis against decreasing 
concentrations of urea (4 M, 2 M, 1 M and 0 M) in 50 mM 
Tris–HCl, pH 8, 1 M L- arginine, 0.5 mM EDTA, 0.02% 
sodium azide buffer. Each dialysis step was of 2 hours. 
BLS- MICA was stored at 4°C. The fraction containing the 
recombinant protein was analyzed by SDS- PAGE.
Production of mouse cell lines stably expressing MICA
The mouse lymphoma cell line EL4 (ATCC TIB-39) and 
the bladder carcinoma MB49,25 both of C57BL/6 back-
ground, were transduced to express the MICA*008 allele 
on their cell surface. For expression of human MICA, cells 
were infected with retroviruses encoding this MICA allele 
and also the puromycin resistance gene. For retrovirus 
production, the packaging cell line PT67 was transfected 
with viral DNA (pMSCV and pMSCV/MICA*008) and 
the packaging vectors (pCMVgag- pol and pMD2.G) using 
FUGENE HD Transfection Reagent (Promega). pMSCV 
(negative control) and pMSCV/MICA*008 (encoding the 
MICA*008 allele) viral DNA were kindly provided by Dr 
Alessandra Zingoni and Dr Angela Santoni from the Labo-
ratory of Molecular Immunology and Immunopathology, 
Department of Molecular Medicine, Sapienza University 
of Rome, Italy. After 48 hours, virus- containing superna-
tants were harvested, filtered, and used for infection as 
follows: 1 mL of viral supernatants containing polybrene 
(8 mg/mL) was used to infect 5×105 EL4 and MB49 cells for 
2 hours. Cells were cultured in the presence of puromycin 
(Enzo Life Sciences). Cells expressing high amounts of 
MICA were screened by flow cytometry (FC) with the anti- 
MICA/B mAb 6D4 labeled with PE (Biolegend). Positive 
cells for MICA were further selected by cell sorting (FACS) 
with the anti- MICA/B mAb 6D4 labeled with PE, cultured 
and stored until use. Thereafter, another round of infec-
tion, selection and sorting was performed. After these two 
rounds of infection, cells were reanalyzed by FC with the 
anti- MICA/B mAb 6D4, the anti- MICA mAb 159 227 or the 
anti- MICB mAb 236 511 and acquired in a FACSCanto II FC 
(BD). Cell sorting was performed in a FACSAria II plus cell 
sorter (BD).
Immunization of mice and collection of sera for passive 
immunization
C57BL/6 mice were obtained from the animal facility of 
the School of Veterinary, University of La Plata (Argen-
tina) and housed at the animal facility of the Institute of 
Biology and Experimental Medicine according to NIH 
guidelines. Mice (6–10- weeks old) were immunized with 
BLS or BLS- MICA by intraperitoneal inoculation (10 or 
20 µg/mouse, respectively, in order to compensate for the 
different molecular mass of each immunogen), with or 
without complete Freund’s adjuvant (CFA). Mice received 
one immunization every 2 weeks and 1 week after the last 
immunization, blood samples were obtained by venipunc-
ture from the facial vein, and sera were obtained and 
analyzed for the presence of anti- MICA pAb by ELISA. 
Sera from mice with high titers of anti- MICA pAb were 
collected and stored at −20°C for passive transfer studies. 
As titration of the sera by ELISA with rMICA as coating 
antigen showed that mice immunized with BLS- MICA 
with or without CFA developed a similar titer of anti- MICA 
pAb, subsequent immunizations aimed at obtaining sera 
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studies with mice have been approved by the institutional 
review committee for animal care.
eLIsA
Polystyrene plates (High binding, Costar) were coated 
with 1 µg/mL of rMICA*001 produced and used as previ-
ously described26 or BLS- MICA. After blocking with 5% 
non- fat dry milk in phosphate buffered saline (PBS) 
for 1 hour at 37°C, plates were incubated with an anti- 
MICA or an anti- BLS mAb, with rabbit anti- MICA pAb or 
with serial dilutions of sera from the different mice for 
1 hour at 37°C, washed with PBS- Tween 20 0.05%, incu-
bated with horseradish peroxidase (HRP)- labeled anti- 
mouse or anti- rabbit IgG for 1 hour at 37°C, washed and 
developed with H2O2 and 3,3′,5,5′-tetramethylbenzidine. 
Optical density was determined in a Thermo Multiscan 
FC ELISA reader at 450 nm.
Flow cytometry
Expression of cell surface receptors and markers was 
analyzed by FC using fluorochrome- labeled mAb as 
previously described.27 28 Data were acquired in a 
MACSQuant10 (Miltenyi Biotec) or a FACSCanto II (BD) 
flow cytometers, analyzed using FlowJo X software (Tree 
Star) and expressed as median fluorescence intensity 
(MFI) or as percentage of positive cells.
Mice and tumor challenge experiments
C57BL/6 mice (6–10 weeks) were used (males and females 
for experiments with EL4 cells and males for experiments 
with MB49 cells). Studies have been approved by the 
institutional ethics review committee. Control or MICA- 
expressing EL4 or MB49 tumor cells were inoculated by 
subcutaneous route in one flank of the animals (2×105 
cells per mouse), tumor size was measured using a caliper 
and tumor volume was calculated by the modified ellip-
soidal formula (length × width2)/2 as described.9 For 
active prophylactic immunization experiments mice were 
immunized four times by intraperitoneal route with BLS 
or with BLS- MICA (10 or 20 µg/mouse, respectively) 
without adjuvants every 9–10 days. Three weeks after the 
last immunization, mice were challenged with MB49- 
MICA*008 tumor cells, and tumor growth was assessed. 
For passive therapeutic immunization experiments, once 
tumors reached a palpable/measurable size (between 7 
and 10 days after inoculation), mice were passively immu-
nized by intraperitoneal route with 200 µL of a 1/4 dilu-
tion of a pool of sera from mice previously immunized with 
BLS (control pAb, Ctrl pAb) or with a similar volume of 
a pool of sera from mice previously immunized with BLS- 
MICA (anti- MICA pAb) every 2 days until the euthanasia 
of each animal. In some experiments, mice were eutha-
nized after 12 days of tumor inoculation and tumors were 
collected to analyze the composition of the cell infiltrate. 
For active therapeutic immunization experiments, 1 day 
after tumor challenge, mice were actively immunized by 
intraperitoneal route with BLS or with BLS- MICA (10 or 
20 µg/mouse, respectively) without adjuvants every 7 days 
until the euthanasia of each animal. Additionally, adju-
vant treatment simulation was assessed, for which mice 
were challenged with control or MICA- expressing MB49 
tumor cells, tumors were removed by surgery when they 
became palpable (about 1 week after the inoculation) 
and mice were thereafter treated with Ctrl pAb or anti- 
MICA pAb as described above. For these experiments, 
mice received tramadol (40 mg/kg) in drinking water just 
before and after surgery. To mitigate risk of infections, 
surgery wound was cleaned with thimerosal and mice 
received enrofloxacin (50 mg/kg) in drinking water for 
2 days before surgery and up to 2 days after finishing the 
experiment. Also, in vivo ADCC was assessed using tumor 
cells that were incubated with sera from mice immunized 
with BLS- MICA or with BLS alone as described below, 
were injected in naive C57BL/6 mice by subcutaneous 
route and tumor growth was assessed. In all cases, tumor 
growth was assessed as described and animals were eutha-
nized when tumors reach a size of 1000 mm3. Also, exper-
iments with MB49 cells were terminated earlier as these 
tumors tend to ulcerate and due to ethical reasons, mice 
were euthanized if their tumors ulcerated.
AdCC in vitro
Control or MICA- expressing tumor cells were labeled with 
eFluorDye670 (eBiosciences) for 15 min at 37°C, washed 
and incubated with sera from mice immunized with BLS- 
MICA or with BLS alone for 30 min. The excess of pAb 
was washed, and tumor cells were incubated with mouse 
NK cells isolated from spleens from healthy C57BL/6 
mice using a positive selection reagent (Miltenyi) for 
5–6 hours. Thereafter, viability in the eFluorDye670 
population (target cells) was assessed using Zombie-
Acqua (Biolegend) and FC using a MACSQuant10 flow 
cytometer. Data were analyzed using FlowJo X software, 
and results were expressed as percentage of cytotoxicity 
calculated as the percentage of ZombieAcqua+ cells in the 
eFluorDye670+ cell population.
AdCC in vivo
Control or MICA- expressing tumor cells were labeled 
with carboxyfluorescein succinimidyl ester (CFSE) or 
eFluorDye670 (eBiosciences), respectively, for 15 min 
at 37°C, washed, mixed in equal proportions and incu-
bated with sera from mice immunized with BLS- MICA or 
with BLS alone for 1 hour. Then, 4×105 tumor cells were 
injected in naive C57BL/6 mice by subcutaneous route. 
After 72 hours, mice were euthanized, cells were recov-
ered from the inoculation site, and the relative abun-
dance of CFSE+ and eFluorDye670+ cells was analyzed by 
FC using a MACSQuant10 flow cytometer and expressed 
as percentage of recovered cells. Data were analyzed 
using FlowJo X software. In other experiments, unla-
beled control or MICA- expressing tumor cells were incu-
bated with sera from mice immunized with BLS- MICA 
or with BLS alone as described before, injected in naive 
C57BL/6 mice by subcutaneous route and tumor growth 
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Figure 1 MICA RNA is overexpressed in the human tumors that exhibit high number of deaths compared with matched normal 
tissues. RNAseq data of expression of different NKG2DL (indicated at the top of each panel) in the indicated human tumors. 
The red horizontal line in each graph indicates the cut- off value to consider upregulated expression. Data presented were 
obtained from the cBioPortal for cancer genomics (http://www.cbioportal.org/). The graph corresponds to 1084 breast tumors, 
594 colorectal tumors, 372 liver tumors, 566 lung adenocarcinomas, 487 lung squamous cell carcinomas and 440 stomach 
carcinomas. MICA, MHC class I chain- related protein A; MICB, MHC class I chain- related protein B; NKG2DL, ligand of NKG2D.
Analysis of soluble MICA
Analysis of sMICA in sera of mice was performed by an 
in- house developed system. Briefly, avidin- coated micro-
spheres (SPHERO Avidin Coated Particles, Spherotech) 
were coated with biotinylated anti- MICA/B mAb 6D4 
and used to capture sMICA from sera of different groups 
of mice for 16 hours. Microspheres were washed and 
bound sMICA was detected with AlexaFluor488- labeled 
anti- MICA mAb 159 227 by FC using a MACSQuant10 
flow cytometer. Data were analyzed using FlowJo X soft-
ware and results were expressed as MFI. The analysis was 
performed using sera of mice that were euthanized after 
15 days of tumor challenge.
statistical analysis
Two- way analysis of variance (ANOVA) with Sidak’s 
posthoc tests were used for comparison of tumor growth. 
For comparison of two experimental groups, unpaired 
two- tailed Student’s t- tests were used. For Kaplan- Meier 
analysis, log- rank Mantel- Cox test was used. Data were 
analyzed using GrapPad Prism V.6.0 software.
resuLts
MICA is overexpressed in tumors including those that display 
the highest number of deaths and incidence
According to GLOBOCAN (https:// gco. iarc. fr/), lung, 
colorectal, stomach, liver and breast cancers exhibit the 
highest number of deaths. To explore the expression of 
NKG2DL in these types of tumors, we performed a bioin-
formatic analysis of their expression. The analysis of RNA 
sequencing (seq) data in the cBioportal database (http://
www. cbioportal. org/)20 21 showed that all these tumors 
expressed MICA, MICB and the 6 ULBP (figure 1). 
However, MICA was the NKG2DL that exhibited the most 
homogeneous expression within each of these tumors 
and among them, MICA was the NKG2DL that exhib-
ited the highest expression. Therefore, we focused our 
study on MICA, as its overexpression in human tumors 
that exhibit a high mortality suggests a potential role for 
MICA as target for an Ab- mediated therapy.
Immunization with the chimeric bLs-MICA protein generates 
high titer of anti-MICA Ab that recognize the cell surface 
expressed form of MICA
Reasoning that MICA constitutes a potential target for 
Ab- mediated antitumor therapy, we devised a strategy 
to generate pAb against this human NKG2DL using a 
chimeric protein. First, we produced this chimeric/
immunogenic protein (named BLS- MICA) that combines 
the immunogenic scaffold provided by BLS coupled to 
the ectodomain of MICA (table 1). This protein was 
produced in bacteria as inclusion bodies. After solubi-
lization, refolding and removal of the urea used during 
solubilization, this protein displayed the expected size 
(~49 kDa) by SDS- PAGE analysis (not shown). Moreover, 
BLS- MICA was recognized by an anti- MICA/B mAb D7 
(previously produced in our laboratory22), by an anti- BLS 
mAb (BI24, figure 2A), and by rabbit pAb produced 
against peptides of the α1 or the α2 domains of MICA23 
(figure 2B). Next, this chimeric protein was used to 
immunize C57BL/6 mice with or without the use of CFA 
following a standard immunization schedule (outlined in 
figure 2C). Only mice immunized with BLS- MICA (with 
or without CFA) developed anti- MICA pAb (figure 2D). 
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Figure 2 Immunization of mice with BLS- MICA generates high titers of anti- MICA pAb. (A) ELISA with plates coated with 
BLS- MICA and incubated with serial dilutions of an anti- MICA/B (D7, red) or an anti- BLS (BI24, blue) mAb. (B) ELISA with 
plates coated with BLS- MICA and incubated with serial dilutions of rabbit pAb raised against peptides spanning the α1 (#620 
and #621) or the α2 (#622) domains of MICA. (C) Outline of the immunization schedule used to immunize C57BL/6 mice. After 
3, 5 and 7 weeks of starting the protocol, blood samples were collected from the animals (indicated by numbers 1, 2 and 3, 
respectively) to analyze the presence of anti- MICA pAb. (D) ELISA with plates coated with rMICA and incubated with serial 
dilutions of sera from mice collected after 3 (blue), 5 (yellow) and 7 (red) weeks after starting the immunization protocol. Graphs 
show representative results of one immunization plan performed with five animals per group immunized with BLS alone, BLS 
and CFA, BLS- MICA alone or BLS- MICA and CFA. Mean±SEM is shown. Ab, antibody; BLS, Brucella lumazine synthase; BLS- 
MICA, BLS coupled to MICA; CFA, complete Freund’s adjuvant; mAb, monoclonal antibody; MICA, MHC class I chain- related 
protein A; MICB, MHC class I chain- related protein B; NRS, normal rabbit serum; pAb, polyclonal Ab.
without CFA. Sera with high titer of anti- MICA pAb were 
pooled and used for further experiments.
A critical step to evaluate our hypothesis was the in vivo 
testing of the therapeutic efficacy of the anti- MICA pAb 
in mouse models. As mice do not have the MICA gene 
and consequently do not express MICA, we generated 
two mouse cell lines (EL4 and MB49) engineered to 
express the most frequent allele of MICA (MICA*008, 
www. allelefrequencies. net) on their cell surface using 
retroviral vectors. After two rounds of infection, we 
obtained control cell lines (EL4- pMSCV and MB49- 
pMSCV), and cell lines expressing MICA*008 (EL4- 
MICA*008 and MB49- MICA*008) on their cell surface 
(figure 3A) that did not display differences in their in 
vitro growth rate (not shown). Moreover, anti- MICA pAb 
generated with BLS- MICA bound to MB49- MICA*008 
cells, suggesting that BLS- MICA elicits Ab activity against 
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Figure 3 Mouse cell lines transduced with retroviral vectors encoding MICA express high amounts of this NKG2DL on their 
cell surface that is recognized by sera of mice immunized with BLS- MICA. (A) EL4 and MB49 cells were infected with control 
(empty) retroviruses (pMSCV) or with retroviruses encoding MICA*008 to generate the EL4- pMSCV, EL4- MICA*008, MB49- 
pMSCV and MB49- MICA*008 cell lines, and expression of MICA was assessed with the 6D4 mAb (anti- MICA/B), the anti- MICA 
mAb 159 227 or the anti- MICB mAb 236 511 by FC. Gray: IC mAb; black lines: anti- MICA/B, anti- MICA or anti- MICB mAb. 
HCT116 cells: positive control for MICA and MICB expression. (B) MB49- pMSCV, MB49- MICA*008 and HCT116 cell lines 
were labeled using a pool of sera of mice immunized with BLS- MICA (‘anti- MICA’, black line histogram) or with normal mouse 
serum (preimmune, gray histogram) and analyzed by FC. Ab, antibody; BLS, Brucella lumazine synthase; FC, flow cytometry; 
IC, isotype control; BLS- MICA, BLS coupled to MICA; mAb, monoclonal antibody; MICA, MHC class I chain- related protein A; 
MICB, MHC class I chain- related protein B; NKG2DL, ligand of NKG2D.
from tumors that exhibit the highest number of deaths 
and considering that we were interested in MICA as 
promising target for immuno- oncology, we selected 
the EL4 and MB49 mouse tumor models due to their 
C57BL/6 background, their availability and the fact 
that they constitute one model of liquid tumor and one 
model of solid tumor, both of which could be enforced 
to express MICA.
Immunization with the chimeric bLs-MICA protein generates 
a therapeutic effect against MICA-expressing tumors that is 
mediated by anti-MICA pAb
Active immunization with BLS-MICA delays growth of tumors that 
express MICA
To assess the effect of the immunization with BLS- MICA 
on tumor growth, mice were challenged with MB49- 
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Figure 4 Immunization with BLS- MICA delays growth of tumors that express MICA. (A) Outline of the active immunization 
and tumor challenge schedule. Mice were immunized with BLS or BLS- MICA as indicated (four immunizations). Then, mice 
were rested for 3 weeks, challenged with MB49- MICA*008 tumors, and tumor growth was assessed. (B) Pie charts showing the 
percentage of mice immunized with BLS (left) or BLS- MICA (right) that developed palpable tumors at day 8 after challenge. (C) 
Tumor growth curves in mice immunized with BLS (blue) or with BLS- MICA (red). Mean±SEM is shown. Statistically significant 
differences between groups started at day 8 after tumor challenge. ****p<0.0001, two- way ANOVA with Sidak’s posthoc test. 
(D) Amounts of sMICA (expressed as MFI) detected in sera of mice immunized with BLS (blue dots) or BLS- MICA (red dots) and 
challenged with MB49- MICA*008 tumor cells at the time of euthanasia (15 days after tumor challenge). Each dot corresponds 
to one mouse (**p=0.008, unpaired two- tailed Student’s t- test. (E) Correlation analysis between the amount of sMICA and tumor 
volume (R Spearman=0.7706, p<0.0001). Data from mice immunized with BLS (blue) or with BLS- MICA (red) were plotted 
together. Data shown in the graph correspond to cumulative results from two independent experiments. n=14 mice per group 
(B–D) and n=28 (E). ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS- MICA, BLS coupled to MICA; MFI, 
median fluorescence intensity; MICA, MHC class I chain- related protein A; MICB, MHC class I chain- related protein B; sMICA, 
soluble MICA.
with BLS- MICA or with BLS alone. However, we did not 
observe differences in the tumor growth between both 
groups (not shown), likely due to the rapid tumor growth 
which is much faster than the time required to elicit an 
effective anti- MICA immune response and a hypothetical 
therapeutic effect. Therefore, we set- up a prophylactic 
immunization protocol in which naive mice were immu-
nized four times with BLS or with BLS- MICA, and after 
3 weeks, mice were challenged with MB49- MICA*008 
cells as outlined in figure 4A. We selected MB49 cells as 
this tumor grows slower in vivo, providing a more suit-
able experimental approach to test our hypothesis. We 
observed that 100% of the mice immunized with BLS 
developed palpable tumors at day 8 after challenge but 
that only 79% of mice immunized with BLS- MICA devel-
oped palpable tumors at day 8 after challenge (figure 4B). 
Although mice without tumor did eventually develop 
tumors, the analysis of tumor growth revealed that active 
immunization with BLS- MICA induced a statistically 
significant slower tumor growth of MICA- expressing 
tumors than immunization with BLS (figure 4C). In 
addition, mice immunized with BLS- MICA exhibited 
lower amounts of sMICA in serum than mice immunized 
with BLS (figure 4D). In the control group (mice immu-
nized with BLS), we observed that 5/13 mice displayed 
high sMICA and 8/13 displayed low sMICA. Although in 
these experiments we did not analyze if this difference 
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MICA; additional data indicate that mice challenged 
with MICA- expressing tumors can develop endogenous/
spontaneous anti- MICA Ab (online supplementary figure 
1). Therefore, the difference between these two groups 
of mice challenged with MICA+ tumors might be due to 
a different endogenous response against MICA. More-
over, there was a positive correlation between sMICA 
and tumor volume (figure 4E). Therefore, prophylactic 
immunization with BLS- MICA appears to trigger a protec-
tive immune response that promotes scavenging of sMICA 
likely mediated by pAb against MICA.
Passive immunization of tumor-bearing mice with anti-MICA pAb 
produced with BLS-MICA delay growth of tumors that express 
MICA and reshape the tumor microenvironment
To confirm this hypothesis, we challenged C57BL/6 
mice with EL4- pMSCV, EL4- MICA*008, MB49- pMSCV or 
MB49- MICA*008 cells and, once tumors were palpable, 
mice were passively immunized with a pool of sera from 
mice immunized with BLS (Ctrl pAb) or with BLS- MICA 
(anti- MICA pAb), as outlined in figure 5A. In the case of 
EL4 tumors, when we analyzed the proportion of mice 
that developed tumors greater than 500 mm3 at day 11 
after challenge, we observed that 100% of mice challenged 
with control tumors experienced tumor development 
regardless of the treatment, that 75% of mice challenged 
with MICA- expressing tumors and treated with Ctrl pAb 
developed tumors but that none of the mice challenged 
with MICA- expressing tumors and treated with anti- MICA 
pAb developed tumors (figure 5B). Moreover, in the 
case of MB49 tumors, we observed that the anti- MICA 
pAb induced a significant delay in tumor growth in mice 
challenged with MICA- expressing tumors, compared with 
mice treated with Ctrl pAb and challenged with MICA- 
expressing tumors or to mice treated with Ctrl pAb or 
anti- MICA pAb and challenged with control tumors 
(figure 5C). The therapeutic effect of the anti- MICA pAb 
on MICA expressing tumors resulted in an extended 
survival, as indicated by the Kaplan- Meier analysis of both 
models, EL4 and MB49 tumors (figure 5D). Remarkably, 
some mice challenged with MB49- MICA*008 and treated 
with anti- MICA pAb displayed complete tumor regres-
sion and these mice (n=3/8) remained tumor- free for 
more than 2 months, even without continuous passive 
administration of anti- MICA pAb (which was stopped at 
day 19 after tumor challenge), indicating that the robust 
therapeutic effect was long- lasting. Moreover, to investi-
gate if anti- MICA pAb can affect tumor recurrence, mice 
were challenged with MB49- pMSCV or MB49- MICA*008 
cells, tumors were removed by surgery once they became 
palpable and then the animals were passively immunized 
with Ctrl pAb or anti- MICA pAb and monitored for tumor 
reappearance (figure 5E). Notably, all mice challenged 
with MB49- pMSCV and treated with Ctrl pAb or with 
anti- MICA pAb, as well as mice challenged with MB49- 
MICA*008 tumors and treated with Ctrl pAb developed 
palpable tumors at day 42 after surgery, while only a 50% 
of mice challenged with MB49- MICA*008 tumors and 
treated with anti- MICA pAb developed palpable tumors 
at that time. These results indicate that the anti- MICA 
Ab delay re- emergence of tumors if they express this 
NKG2DL.
the therapeutic effect of anti-MICA pAb generated 
with bLs-MICA include a reprogramming of the tumor 
microenvironment and stimulation of AdCC
To analyze the effect of the anti- MICA pAb on the char-
acteristics of the tumor cell infiltrate, mice bearing 
MB49- MICA*008 tumor cells were passively immunized 
with anti- MICA pAb or with control pAb by intraperito-
neal route following the previously described scheme 
(figure 5A), euthanized at day 12, and tumors were 
collected to analyze the composition of the infiltrate as 
outlined in online supplementary figure 2. Significant 
differences in the profile of intratumoral macrophages 
(CD11b+F4/80+ cells) and antigen- experienced CD8+ 
T cells were observed in mice that received anti- MICA 
pAb. Intratumoral macrophages of these mice displayed 
higher expression of CD274, CD86 and MHC- II than 
intratumoral macrophages of mice that received Ctrl 
pAb, indicating that they display markers associated with 
a M1/proinflammatory phenotype (figure 5F), concom-
itant with a higher percentage of tumor- infiltrating 
CD8+CD44+ T cells (antigen- experienced CD8+ T cells, 
figure 5G; representative results are shown in figure 5H). 
No differences were observed between groups in terms of 
granulocytic and monocytic myeloid- derived suppressor 
cells (G- MDSC or CD11b+Gr1high cells and M- MDSC or 
CD11b+Gr1low cells, respectively; online supplementary 
figure 3). These results indicate that anti- MICA pAb can 
reprogram the tumor- infiltrating cells toward an antitu-
moral/proinflammatory phenotype.
Next, to explore the mechanisms that account for the 
therapeutic effect, we assessed whether anti- MICA pAb 
generated with BLS- MICA can promote ADCC, and its 
effect on tumor growth (figure 6). We observed that these 
pAb indeed triggered ADCC in vitro (figure 6A). More-
over, less MICA- expressing tumor cells than control tumor 
cells were recovered after 72 hours of in vivo growth if 
they were preincubated with anti- MICA pAb. In addition, 
similar MICA- expressing tumor cells and control tumor 
cells were recovered after 72 hours of in vivo growth if 
they were preincubated with Ctrl pAb (figure 6B). This 
effect resulted in a strong inhibition of the tumor growth 
as we observed that MICA- expressing tumor cells prein-
cubated with anti- MICA pAb displayed a very slow tumor 
growth compared with MICA- expressing tumor cells pre- 
incubated with Ctrl pAb and to control tumor cells prein-
cubated with control or anti- MICA pAb before injection 
(figure 6C).
Overall, these results indicate that immunization with 
BLS- MICA generates a protective effect against MICA- 
expressing tumors that involves the generation of anti- 
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Figure 5 Anti- MICA pAb passively administered to tumor- bearing mice delay growth of tumors that express MICA associated 
with an increased accumulation of tumor infiltrating M1/proinflammatory macrophages and antigen- experienced CD8+ T cells. 
(A) Outline of the tumor challenge and passive immunization schedule. Mice were challenged with control (EL4- pMSCV or 
MB49- pMSCV) or MICA- expressing (EL4- MICA*008 or MB49- MICA*008) tumors at day 0. When tumors reached a palpable 
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(anti- MICA) every 2 days, and tumor growth was assessed. (B) Pie charts showing the percentage of mice challenged with 
EL4- pMSCV (upper charts) or EL4- MICA*008 (lower charts) cells and immunized with Ctrl pAb (left) or anti- MICA (right) that 
developed tumors greater than 500 mm3 at day 11 after challenge. The tumor volume of 500 mm3 was selected because in our 
experience tumors of that size invariably progress. (C) Tumor growth curves of MB49- pMSCV (left) or MB49- MICA*008 (right) 
cells, in mice treated with Ctrl pAb or with anti- MICA pAb. **p<0.01, ****p<0.0001, two- way ANOVA with Sidak’s posthoc test. 
(D) Kaplan- Meier curves corresponding to mice challenged with EL4- MICA*008 cells (upper graph) or MB49- MICA*008 cells 
(lower graph) and treated with Ctrl pAb or with anti- MICA pAb. Differences between the two groups were significant (*p=0.0223 
for EL4- MICA*008 cells and **p=0.016 for MB49- MICA*008 cells, log- rank Mantel- Cox test). Of note, it was not possible to 
extend the experiments up to 120 days with MB49 cells as these tumors tend to ulcerate and due to ethical reasons, mice were 
euthanized. (E) Pie charts showing the percentage of mice challenged with MB49- pMSCV (upper charts) or MB49- MICA*008 
(lower charts) cells that underwent surgery to remove the tumor and that were then immunized with Ctrl pAb (left) or anti- 
MICA (right) that developed palpable tumors at day 42 after surgery (tumors of more than 60 mm3). n=4 per group (B–E). Data 
shown in B to E correspond to one representative experiment which was performed twice with similar results. (F–H) Mice were 
challenged with MB49- MICA*008 tumor cells and passively immunized with control pAb (Ctrl Ab, blue dots) or with anti- MICA 
pAb (anti- MICA, red dots) every 2 days starting when tumor became palpable as indicated in panel A. After 12 days, mice were 
euthanized, and the composition of the tumor infiltrate was analyzed by FC (outlined in online supplementary figure 2). (F) MFI 
of CD274, CD86 and MHC- II in F4/80+ cells (macrophages). (G) Percentage of CD44+CD8+ cells. (H) Representative histograms 
(numbers correspond to MFI) of CD274, CD86 and MHC- II in F4/80+ cells (macrophages) and pseudocolor plots (numbers 
correspond to percentages) of CD44+CD8+ cells. Each dot in F and G represents the data from one mouse. Data shown in 
the graphs correspond to cumulative results from two independent experiments. **p<0.01, ***p<0.001. An unpaired two- tailed 
Student’s t- test was used in F and G. CD274: n=9 (Ctrl Ab), n=10 (anti- MICA Ab), p=0.0007. CD86: n=8 (Ctrl Ab and anti- MICA 
Ab), p=0.0016. MHC- II: n=8 (Ctrl Ab and anti- MICA Ab), p=0.0032. CD44+: n=7 (Ctrl Ab), n=8 (anti- MICA Ab), p=0.0016. Ab, 
antibody; ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS- MICA, BLS coupled to MICA; Ctrl Ab, control Ab; 
FC, flow cytometry; MFI, median fluorescence intensity; MICA, MHC class I chain- related protein A; MICB, MHC class I chain- 
related protein B pAb, polyclonal Ab.
dIsCussIon
During the last years, MICA emerged as an attractive 
target for Ab- mediated immunotherapy strategies in 
patients with cancer due to its overexpression in a wide 
variety of human tumors. The possibility of MICA being a 
target for Ab in human patients was first demonstrated in 
individuals with solid transplant rejection.26 Later, a signif-
icant correlation between anti- MICA Ab and graft loss 
was described.29 In a tumor setting, it has been demon-
strated that anti- MICA Ab spontaneously arise in patients 
treated with an anti- CTLA4 mAb and vaccinated with 
lethally irradiated, autologous tumor cells engineered 
to secrete granulocyte–macrophage colony- stimulating 
factor. Moreover, such spontaneously induced anti- MICA 
Ab promoted scavenging of sMICA and interfered with 
tumor- immune escape, resulting in a recovery of NK and 
CD8+ T cell- mediated cytotoxicity and a better course of 
the disease.12 13 These results highlight the therapeutic 
potential of anti- MICA Ab for patients with cancer. 
Accordingly, some mAb against MICA that demonstrated 
therapeutic efficacy against tumors in mouse models 
through the promotion of mAb- mediated neutralization 
of sMICA14 or inhibition of MICA/B shedding and stabi-
lization of cell surface expression of MICA/B15 have been 
developed.
In this work, we hypothesized that active induction of 
anti- MICA pAb could represent a novel opportunity for 
some unmet medical needs. On one hand, used as primary 
treatment, alone or combined with other strategies, such 
pAb may reinstate antitumor immunity in patients with 
tumors that express MICA. But on the other hand, an 
active induction of anti- MICA pAb may represent a novel 
prophylactic approach useful for patients with cancer as 
adjuvant therapy after surgical excision, chemotherapy 
or radiotherapy of the primary tumor in order to reduce 
the risk of tumor recurrence of the primary tumor and/
or development of metastases. To generate an immu-
nogen useful to induce anti- MICA pAb, we used an estab-
lished platform suitable to produce highly immunogenic 
chimeric proteins based on the use of BLS, a lumazine 
synthase from Brucella spp.17–19 We generated a chimeric 
protein in which we coupled the ectodomain of MICA 
to BLS. This chimeric protein was highly immunogenic 
in mice and elicited high titers of anti- MICA pAb, even 
without the use of additional adjuvants, and recognized 
MICA naturally expressed on the cell surface of human 
tumor cells and on mouse tumor cells engineered to 
express MICA. Prophylactic active immunization with 
BLS- MICA was sufficient to significantly delay the growth 
of MICA- expressing tumors in part due to the ability to 
promote scavenging of sMICA from mouse sera. More-
over, there was a linear association between sMICA 
levels and tumor size. These results support our working 
hypothesis and suggest that BLS- MICA might function as 
an antitumor vaccine. Remarkably, we used one allele to 
produce the chimeric protein (MICA*001) and another 
allele for the transduction of the cell lines (MICA*008) in 
order to develop a strategy that is independent of allele- 
specific pAb. In this way, we mitigated the risk of eliciting 
antitumor immunity that is mediated by allele- specific 
pAb and generated pAb with the chimeric protein that 
can trigger antitumor immunity even against tumors that 
express another allele (MICA*008) which, on the other 
hand, is the most frequent allele in the population.
To further explore the mechanism underlying this anti-
tumor effect and using a passive immunization approach, 
we demonstrated that such effect was mediated by anti- 
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Figure 6 Anti- MICA pAb passively administered to tumor- bearing mice promote ADCC. (A) In vitro ADCC of mouse NK cells 
against MB49- pMSCV or MB49- MICA*008 cells preincubated with control pAb (Ctrl Ab) or anti- MICA pAb (anti- MICA) assessed 
at 2 E:T ratios (indicated in the x- axis). YAC-1 cells were used as positive control of NK cell- mediated cytotoxicity. (B) In vivo 
ADCC against MB49- pMSCV (yellow dots) or MB49- MICA*008 tumor cells (green dots) preincubated with control pAb (Ctrl 
Ab) or anti- MICA pAb (anti- MICA). The relative abundance of CFSE+ and eFluorDye670+ cells (each tumor cell) recovered after 
72 hours of subcutaneous challenge of naive mice with tumor cells preincubated with control or anti- MICA pAb was analyzed by 
FC. An unpaired two- tailed Student’s t- test was used. ****p<0.0001. (C) Tumor growth of tumor cells preincubated with control 
or anti- MICA pAb injected in naive mice. MB49- pMSCV (blue and green dots) or MB49- MICA*008 tumor cells (yellow and red 
dots) were incubated in vitro with control pAb (Ctrl Ab, blue and yellow dots) or anti- MICA Ab (green and red dots), injected in 
naive mice and tumor growth was assessed. Each dot in B and C correspond to one mouse. n=4 per group (B, C). Data shown 
correspond to one representative experiment which was performed twice with similar results. ****p<0.0001, two- way ANOVA 
with Sidak’s posthoc test. Ab, antibody; ADCC, antibody- dependent cell- mediated cytotoxicity; ANOVA, analysis of variance; 
CFSE, carboxyfluorescein succinimidyl ester; Ctrl Ab, control Ab; FC, flow cytometry; MFI, median fluorescence intensity; MICA, 
MHC class I chain- related protein A; pAb, polyclonal Ab.
antitumor effect was observed with two different mouse 
tumors (EL4 lymphoma and MB49 bladder carcinoma) 
engineered to express MICA*008, with no effects on 
control tumor cells that do not express this NKG2DL, 
suggesting that the approach of using anti- MICA pAb as 
immunotherapy might be a strategy applicable to tumors 
of different histotypes. This is reinforced by the bioin-
formatic analysis performed here which showed MICA 
overexpression in a variety of tumors, including those that 
exhibit high number of deaths. Of note, in some animals 
challenged with MICA- expressing tumors and treated 
with anti- MICA pAb, we observed complete tumor regres-
sion. We also established that the anti- MICA pAb elicited 
with BLS- MICA tilted the balance of tumor- infiltrating 
cells toward an antitumoral/proinflammatory pheno-
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associated with proinflammatory macrophages in intra-
tumoral macrophages, and an increased percentage of 
antigen- experienced CD8+ T cells. The underlying mech-
anisms for this therapeutic efficacy include the stimula-
tion of ADCC by the anti- MICA pAb that resulted in a 
delayed tumor growth, as we demonstrated in vitro and 
in vivo.
Therefore, the use of BLS- MICA as vaccine to induce 
therapeutic anti- MICA pAb constitutes a ‘two- in- one’ 
strategy as such pAb may promote tumor elimination 
through ADCC and simultaneously interfere with a 
tumor- immune escape mechanism through scavenging 
of sMICA. Essentially, this is because the ectodomain of 
MICA that is the target for ADCC- mediated therapeutic 
effects is almost identical to the soluble form of MICA. 
Actually, it is possible to target MICA with pAb or mAb. In 
this work, we explored the strategy of eliciting pAb against 
this NKG2DL using an immunogenic chimeric protein. 
However, anti- MICA mAb also are showing promising 
results.14 15 Regardless of the strategy (mAb or pAb), it is 
convenient that Ab that target MICA- expressing tumors 
should trigger ADCC and scavenging of sMICA, as such 
Ab will likely display therapeutic activity in patients with 
tumors that express MICA on their cell surface, tumors 
that shed significant amounts of sMICA or both, and 
such therapeutic efficacy in last instance will depend on 
the relative amounts of cell surface versus soluble MICA 
expressed by any particular tumor type. Moreover, as 
ADCC and scavenging of immune complexes depend on 
FcR, Ab with FcR- binding activity will promote efficient 
tumor regression through one or both mechanisms. In 
this regard, a dimorphism in MICA (position 129) is asso-
ciated with significantly higher amounts of sMICA and 
progression of multiple myeloma,30 highlighting the rele-
vance of targeting both, membrane and soluble MICA 
with Ab as immunotherapy. It is important to mention that 
shed MICA has been also reported to be associated with 
exosomes instead of soluble molecule released by metal-
loproteases, and that such exosome- associated MICA also 
promotes immune suppression.31 Besides, anti- MICA Ab 
(either pAb or mAb), probably can also target this form 
of MICA and contribute to the restoration of tumor 
immunity. Also, as some chemotherapeutic drugs have 
been shown to stimulate MICA shedding,32 strategies that 
combine chemotherapeutic regimes with anti- MICA Ab 
appear as promising approaches.
At this point, we can imagine some limitations of our 
approach. The first one is that we immunized mice with a 
human protein (MICA). The high titer of anti- MICA Ab 
that we generated might be in part because in this setting, 
it is not necessary to break tolerance. Although this intro-
duces a potential limitation in the translation to human 
patients, the fact that some tumor- bearing patients spon-
taneously developed anti- MICA Ab12 13 indicates that it 
is possible to break tolerance to a self, human protein. 
Other limitations could be antigen down- modulation by 
the tumors and/or the selection of resistant tumor cells 
that lost MICA expression (as a consequence of a selective 
killing of tumor cells that express the target), and the 
occurrence of off target and side/unwanted effects during 
clinical trials in human beings. However, regarding the 
chimeric protein itself, we consider that the use of BLS as 
scaffold for the immunogen is safe as this protein is natu-
rally expressed by Brucella spp, the bacteria that causes 
human brucellosis, there are no reports of infected indi-
viduals that exhibit infection- triggered autoimmunity 
and pAb against BLS arise naturally during such infec-
tions but their titer decreases after successful treatment 
of the patients with antibiotics. Therefore, anti- BLS pAb 
do not seem to cause unwanted effects in human patients 
and BLS- MICA appears as a promising approach to break 
tolerance against MICA in human patients.
We believe that vaccination with BLS- MICA may consti-
tute a groundbreaking twist in the field of immuno- 
oncology as this vaccination approach elicits a polyclonal 
response with only a limited number of doses that could 
be therapeutically effective in patients bearing a broad 
range of neoplastic diseases as MICA is widely expressed 
by different tumors.6 9 33–44 Remarkably, this approach 
might also be suitable to cover an unmet medical need 
such as the prophylactic treatment of oncologic patients 
that had their primary tumor removed by surgery, or 
after chemotherapy or radiotherapy, as the presence 
of prophylactic anti- MICA pAb may reduce the risk of 
tumor recurrence and/or development of metastases. 
Passive treatment with pAb against MICA elicited with 
BLS- MICA is an unlikely option for the near future due 
to the complication in their obtention after vaccination 
with BLS- MICA. However, considering the recent devel-
opment of mAb against MICA for passive treatment,14 15 
we consider a promising approach the active immuniza-
tion (vaccination) of tumor- bearing patients with BLS- 
MICA (use of BLS- MICA as primary treatment option) 
and/or the vaccination of patients whose primary tumor 
was removed by surgery or treated with chemotherapy 
or immunotherapeutic agents (use of BLS- MICA as 
secondary treatment option to induce anti- MICA pAb 
that may prevent or delay recurrence and/or metastasis). 
In addition, combination of these approaches (chemo-
therapy or immunotherapy and active immunization with 
BLS- MICA, either simultaneous or sequentially), espe-
cially if the chemotherapeutic agent promotes MICA/B 
upregulation as has been described for some drugs45 also 
emerge as promising future therapeutic strategies.
ConCLusIons
As demonstrated in this work, we developed a chimeric, 
highly immunogenic protein consisting of MICA fused 
to BLS that was effective as tumor vaccine through the 
induction of anti- MICA pAb. The immunization with this 
chimeric protein delayed the growth of MICA- expressing 
tumors, promoted scavenging of sMICA, induced ADCC 
against MICA- expressing tumor cells and led to a repro-
gramming of the tumor microenvironment toward an 
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this chimeric protein constitutes an innovative antitumor 
vaccine of potential application in patients with cancer 
who bear tumors that express MICA that might be used as 
monotherapy or as combination therapy for therapeutic 
or prophylactic purposes.
Author affiliations
1Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biologia y 
Medicina Experimental, Buenos Aires, Argentina
2Inmunova, Buenos Aires, Argentina
3Trust in Science, Global Health R&D, GlaxoSmithKline, Collegeville, PA, United 
States
4Oncology, GlaxoSmithKline, Collegeville, PA, United States
5Trust in Science, Global Health R&D, GlaxoSmithKline, Stevenage, United Kingdom
6Fundación Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos 
Aires, Buenos Aires, Argentina
7Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, 
Universidad de Buenos Aires, Buenos Aires, Argentina
Acknowledgements We would like to thank to Dr Alessandra Zingoni 
and Dr Angela Santoni from the Laboratory of Molecular Immunology and 
Immunopathology, Department of Molecular Medicine, Sapienza University of Rome, 
Italy for providing vectors for transduction of mouse cell lines, to Dr Rosana Felice 
from GSK Argentina for her help during this project, and to Dr Gabriel A Rabinovich 
for providing unlimited access to the FACSCanto flow cytometer.
Contributors NT performed and designed most of the experiments and 
analyzed the data. MVR, FS, ADF, RGS, XLRI, SYN, JMS, AZ and MCS contributed 
experimentally to the data presented in figures 3–6 and supplementary figures. 
NG contributed with the in vivo experiments of figures 4 and 5. EA, CL and RP 
contributed to the production of the chimeric protein. CID, MBF, KPM, KWH and 
ISG contributed with critical discussions and design of experiments. VZ and FAG 
contributed to the design of the chimeric protein. NWZ conceived, designed and 
supervised the study and wrote the manuscript. All the authors reviewed the 
manuscript.
Funding This work was supported by grants from the National Agency for 
Promotion of Science and Technology from Argentina (ANPCYT), the National 
Research Council of Argentina (CONICET), the Trust in Science Program from 
GlaxoSmithKline (GSK), the International CentreCenter for Genetic Engineering and 
Technology (ICGEB, Trieste, Italy) and the University of Buenos Aires (UBA), all to 
NWZ. We also thank Fundación Williams and Fundación René Barón for providing 
financial assistance (donations) to our laboratory.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval All studies with mice have been approved by the institutional 
review committee for animal care.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement Data are available in a public, open access 
repository. All data relevant to the study are included in the article or uploaded as 
supplementary information. Data presented in figure 1 are available in a public, 
open access repository. Data presented in the manuscript were generated locally 
and included in the article.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Norberto Walter Zwirner http:// orcid. org/ 0000- 0001- 7098- 359X
reFerenCes
 1 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of 
age. Nature 2011;480:480–9.
 2 Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and 
adaptive immunity to cancer. Annu Rev Immunol 2011;29:235–71.
 3 Zhang J, Basher F, Wu JD. Nkg2D ligands in tumor immunity: two 
sides of a coin. Front Immunol 2015;6:97.
 4 Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid 
early inducible-1 gene (RAE-1) permits natural killer cell- mediated 
rejection of a MHC class I- bearing tumor in vivo. Proc Natl Acad Sci 
U S A 2001;98:11521–6.
 5 Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 
ligands of the NKG2D receptor stimulate tumour immunity. Nature 
2001;413:165–71.
 6 Groh V, Wu J, Yee C, et al. Tumour- Derived soluble MIC ligands 
impair expression of NKG2D and T- cell activation. Nature 
2002;419:734–8.
 7 Salih HR, Rammensee H- G, Steinle A. Cutting edge: down- regulation 
of MICA on human tumors by proteolytic shedding. J Immunol 
2002;169:4098–102.
 8 Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor- Associated MICA 
is shed by ADAM proteases. Cancer Res 2008;68:6368–76.
 9 Fuertes MB, Girart MV, Molinero LL, et al. Intracellular retention 
of the NKG2D ligand MHC class I chain- related gene A in human 
melanomas confers immune privilege and prevents NK cell- mediated 
cytotoxicity. J Immunol 2008;180:4606–14.
 10 van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy 
of B16 melanoma using anti- cytotoxic T lymphocyte- associated 
antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating 
factor (GM- CSF)- producing vaccines induces rejection of 
subcutaneous and metastatic tumors accompanied by autoimmune 
depigmentation. J Exp Med 1999;190:355–66.
 11 Pardoll DM. The blockade of immune checkpoints in cancer 
immunotherapy. Nat Rev Cancer 2012;12:252–64.
 12 Jinushi M, Hodi FS, Dranoff G. Therapy- Induced antibodies to MHC 
class I chain- related protein A antagonize immune suppression 
and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 
2006;103:9190–5.
 13 Dranoff G. Targets of protective tumor immunity. Ann N Y Acad Sci 
2009;1174:74–80.
 14 Zhang J, Liu D, Li G, et al. Antibody- Mediated neutralization of 
soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv 
2017;3:e1602133.
 15 Ferrari de Andrade L, Tay RE, Pan D, et al. Antibody- Mediated 
inhibition of MICA and MICB shedding promotes NK cell- driven 
tumor immunity. Science 2018;359:1537–42.
 16 Du C, Bevers J, Cook R, et al. Mica immune complex formed with 
alpha 3 domain- specific antibody activates human NK cells in a Fc- 
dependent manner. J Immunother Cancer 2019;7:207.
 17 Laplagne DA, Zylberman V, Ainciart N, et al. Engineering of a 
polymeric bacterial protein as a scaffold for the multiple display of 
peptides. Proteins 2004;57:820–8.
 18 Zylberman V, Craig PO, Klinke S, et al. High order quaternary 
arrangement confers increased structural stability to Brucella sp. 
lumazine synthase. J Biol Chem 2004;279:8093–101.
 19 Berguer PM, Mundiñano J, Piazzon I, et al. A polymeric 
bacterial protein activates dendritic cells via TLR4. J Immunol 
2006;176:2366–72.
 20 Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics 
portal: an open platform for exploring multidimensional cancer 
genomics data. Cancer Discov 2012;2:401–4.
 21 Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex 
cancer genomics and clinical profiles using the cBioPortal. Sci Signal 
2013;6:pl1.
 22 Molinero LL, Fuertes MB, Girart MV, et al. Nf- Kappa B regulates 
expression of the MHC class I- related chain a gene in activated T 
lymphocytes. J Immunol 2004;173:5583–90.
 23 Zwirner NW, Fernández- Viña MA, Stastny P. Mica, a new 
polymorphic HLA- related antigen, is expressed mainly by 
keratinocytes, endothelial cells, and monocytes. Immunogenetics 
1998;47:139–48.
 24 Goldbaum FA, Leoni J, Wallach JC, et al. Characterization of an 
18- kilodalton Brucella cytoplasmic protein which appears to be a 
serological marker of active infection of both human and bovine 
brucellosis. J Clin Microbiol 1993;31:2141–5.
 25 Chen F, Zhang G, Cao Y, et al. MB49 murine urothelial carcinoma: 
molecular and phenotypic comparison to human cell lines as a 
model of the direct tumor response to Bacillus Calmette- Guerin. J 
Urol 2009;182:2932–7.
 26 Zwirner NW, Marcos CY, Mirbaha F, et al. Identification of MICA as 
a new polymorphic alloantigen recognized by antibodies in sera of 
organ transplant recipients. Hum Immunol 2000;61:917–24.
 27 Spallanzani RG, Dalotto- Moreno T, Raffo Iraolagoitia XL, 











15Torres N, et al. J Immunother Cancer 2020;0:e000233. doi:10.1136/jitc-2019-000233
Open access
medroxyprogesterone acetate in mice bearing breast tumors 
restrains NK cell effector functions. Cancer Immunol Immunother 
2013;62:1781–95.
 28 Iraolagoitia XLR, Spallanzani RG, Torres NI, et al. Nk cells restrain 
spontaneous antitumor CD8+ T cell priming through PD-1/PD- L1 
interactions with dendritic cells. J Immunol 2016;197:953–61.
 29 Sumitran- Holgersson S, Wilczek HE, Holgersson J, et al. 
Identification of the nonclassical HLA molecules, MICA, as targets 
for humoral immunity associated with irreversible rejection of kidney 
allografts. Transplantation 2002;74:268–77.
 30 Zingoni A, Vulpis E, Cecere F, et al. MICA-129 dimorphism and 
soluble MICA are associated with the progression of multiple 
myeloma. Front Immunol 2018;9:926.
 31 Ashiru O, Boutet P, Fernández- Messina L, et al. Natural killer cell 
cytotoxicity is suppressed by exposure to the human NKG2D ligand 
MICA*008 that is shed by tumor cells in exosomes. Cancer Res 
2010;70:481–9.
 32 Zingoni A, Cecere F, Vulpis E, et al. Genotoxic stress induces 
senescence- associated ADAM10- dependent release of NKG2D MIC 
ligands in multiple myeloma cells. J Immunol 2015;195:736–48.
 33 Watson NFS, Spendlove I, Madjd Z, et al. Expression of the stress- 
related MHC class I chain- related protein MICA is an indicator 
of good prognosis in colorectal cancer patients. Int J Cancer 
2006;118:1445–52.
 34 Salih HR, Antropius H, Gieseke F, et al. Functional expression and 
release of ligands for the activating immunoreceptor NKG2D in 
leukemia. Blood 2003;102:1389–96.
 35 Groh V, Rhinehart R, Secrist H, et al. Broad tumor- associated 
expression and recognition by tumor- derived gamma delta T cells of 
MICA and MICB. Proc Natl Acad Sci U S A 1999;96:6879–84.
 36 Madjd Z, Spendlove I, Moss R, et al. Upregulation of MICA on high- 
grade invasive operable breast carcinoma. Cancer Immun 2007;7:17.
 37 Cho H, Chung J- Y, Kim S, et al. MICA/B and ULBP1 NKG2D ligands 
are independent predictors of good prognosis in cervical cancer. 
BMC Cancer 2014;14:957.
 38 Ribeiro CH, Kramm K, Gálvez- Jirón F, et al. Clinical significance of 
tumor expression of major histocompatibility complex class I- related 
chains A and B (MICA/B) in gastric cancer patients. Oncol Rep 
2016;35:1309–17.
 39 Wang B, Wang Q, Wang Z, et al. Metastatic consequences of 
immune escape from NK cell cytotoxicity by human breast cancer 
stem cells. Cancer Res 2014;74:5746–57.
 40 Jinushi M, Takehara T, Tatsumi T, et al. Expression and role of MICA 
and MICB in human hepatocellular carcinomas and their regulation 
by retinoic acid. Int J Cancer 2003;104:354–61.
 41 Fionda C, Malgarini G, Soriani A, et al. Inhibition of glycogen 
synthase kinase-3 increases NKG2D ligand MICA expression and 
sensitivity to NK cell- mediated cytotoxicity in multiple myeloma cells: 
role of STAT3. J Immunol 2013;190:6662–72.
 42 Jinushi M, Vanneman M, Munshi NC, et al. Mhc class I chain- 
related protein A antibodies and shedding are associated with the 
progression of multiple myeloma. Proc Natl Acad Sci U S A  
2008;105:1285–90.
 43 Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or 
release of NKG2D ligands as immune evasion strategy of human 
neuroblastoma. Neoplasia 2004;6:558–68.
 44 Sconocchia G, Spagnoli GC, Del Principe D, et al. Defective 
infiltration of natural killer cells in MICA/B- positive renal cell 
carcinoma involves beta(2)- integrin- mediated interaction. Neoplasia 
2009;11:662–71.
 45 Zingoni A, Fionda C, Borrelli C, et al. Natural killer cell  
response to Chemotherapy- Stressed cancer cells: role in tumor 
immunosurveillance. Front Immunol  
2017;8:1194.
A
U
TH
O
R
 P
R
O
O
F
